ULTRA-TEST in Grapeseed Oil (CYP 90%/PROP 10%) Injectable, 200 mg/mL, 8 mL vial, Compounded by Wells Pharmacy, Ocala, FL
Published January 11, 2017 · Recall initiated: September 21, 2016
Summary
FDA records drug Class II recall D-0334-2017, published January 11, 2017 and initiated September 21, 2016. Recalling firm: Wells Pharmacy Network LLC; Status: Terminated; Reported quantity: 714 vials; Lot: All lot codes of product prepared between 02/22/2016 and 09/14/2016, within expiry. Known lot code: 03302016@5, 04202016@2, 05172016@5, 06082016@44, 06102016@6, 08042016@14. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility
What to do
Voluntary: Firm initiated · Press Release
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Wells Pharmacy Network LLC
- Distributor
- Nationwide
- Lot
- All lot codes of product prepared between 02/22/2016 and 09/14/2016, within expiry. Known lot code: 03302016@5, 04202016@2, 05172016@5, 06082016@44, 06102016@6, 08042016@14
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAQUAD1(PAP/PHEN/ALPROS/ATRO) 0.9 mg/0.2 mg/20 mcg/0.01 mg/mL Injectable, a) 2 mL and b) 5 mL vials, CompoundedJanuary 11, 2017
- FDASermorelin Acetate/GHRP (2) 9 mg/3 mg Injectable Kit, Compounded by Wells Pharmacy, Ocala FLJanuary 11, 2017
- FDATestosterone Cypionate in Sesame Oil Injectable, 210 mg/mL, 10 mL vial, Compounded by Wells Pharmacy, Ocala,January 11, 2017
- FDAAlprostadil 20 mcg/mL Injectable, a) 5 mL and b) 10 mL vials, Compounded by Wells Pharmacy Network LLC, OcalaJanuary 11, 2017
- FDANicotinamide Adenine Dinucleotide (NADH) - Lyophilized (P.F.) 100 mg Injectable, Compounded by Wells Pharmacy,January 11, 2017
- FDAULTRA-TEST (CYP 80%/PROP 20%) Injectable, 200 mg/mL, 10 mL vial, Compounded by Wells Pharmacy, Ocala, FLJanuary 11, 2017
Questions about this recall
Was ULTRA-TEST in Grapeseed Oil (CYP 90%/PROP 10%) Injectable, 200 mg/mL, 8 mL vial, Compounded by Wells Pharmacy, Ocala, FL recalled?
Yes. FDA published recall D-0334-2017 on January 11, 2017. Reported hazard: Lack of Assurance of Sterility
What should I do if I have this product?
Voluntary: Firm initiated · Press Release